We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Poolbeg Pharma Plc | LSE:POLB | London | Ordinary Share | GB00BKPG7Z60 | ORD 0.02P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.60 | 4.58% | 13.70 | 13.50 | 13.90 | 13.70 | 13.10 | 13.10 | 959,988 | 14:58:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -4.69M | -0.0094 | -14.57 | 68.5M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/6/2023 18:26 | A couple of large late reported shares could be them. | mark10101 | |
06/6/2023 15:37 | Very encouraging that the 115,000 shares offered at 8.30p in the 2 pm auction got picked up. | klosters65 | |
05/6/2023 12:23 | Just seen that their was a trade Friday afternoon for 901,332 shares at 8.20p. | klosters65 | |
05/6/2023 08:47 | I am pleased to see that the share price is continuing to firm up. | klosters65 | |
02/6/2023 09:24 | Are we on the move? | klosters65 | |
01/6/2023 12:21 | That is a decent buy. | rafboy | |
01/6/2023 12:02 | Damn nice trade yesterday at 3:37.. 1.5 Mill at 7.92p | chica1 | |
31/5/2023 13:30 | Forbes:Data mining.. I particularly like this paragraph. Unearthing data by a citizen developer can keep century-old companies alive by taking their wealth of knowledge and applying it going forward. Historical data can define how they make money while guiding the future. Using this data can present new opportunities and skyrocketing revenues. Enterprises with the ability to harness big data can support new revenue streams and create spin-offs, new departments or new services. | chica1 | |
31/5/2023 08:59 | Oh sure Klosters he was telling us over on HVO's forum that Mo was holding back news to let an institutional investor accumulate. | chica1 | |
31/5/2023 08:15 | Trout, You make it sound like a precise piece of engineering. And that is gospel. Believe me it is not. Much can happen between the bid and offer and occasionally the punters can mix with the market makers. | klosters65 | |
30/5/2023 22:05 | klosters, The price is made as a bid and an offer, the MMs bid for your shares and offer you shares at a higher price. The punter buys at the offer price and sells at the bid price. | troutisout | |
30/5/2023 14:54 | Definitely a buy at 7.20p. Now 7.2O Buy. /. 7.50. Ask. | klosters65 | |
28/5/2023 21:35 | Well Ex isn't that when he was doing his monthly fireside chats,2021?? | chica1 | |
27/5/2023 07:49 | He thinks this is an AI share. Lmao. It's only the ones that make the algorithms/models/pl | ih_486726 | |
26/5/2023 16:34 | AI shares exploding upwards because of Nvidia's quarter. Would have been nice to get some AI news in the current climate. | chica1 | |
26/5/2023 14:05 | OneTree news is not due until H2,not Q2. Many thanks for your email enquiry. We have stated publicly we are progressing the drug candidates identified in our OneThree RSV AI programme into lab-based validation and I can confirm that we are on track to announce our progress on this in H2, as per our stated timeline. Keeping to our projected timelines is something that the Poolbeg team takes very seriously, and we aim to continue achieving these. With that in mind, we expect the outputs to the OneThree AI programme to be delivered on schedule. Please do not hesitate to contact us should you have any further questions or queries. Kind regards, Investor Relations | chica1 | |
26/5/2023 12:27 | See post 2429. I'm not privileged to anything that has not been released to the market. | klosters65 | |
26/5/2023 12:20 | What news klosters? | chica1 | |
26/5/2023 11:54 | Pretty convinced that there is not much time left to buy at the current price. Bid is firming up and news must be due shortly. | klosters65 | |
26/5/2023 11:21 | 1gw no doubt he's an intelligent guy but yeah who's pulling the strings. Then again imho most board members are futile, so if he's willing to put the time in (and he does) that's a major asset to have. | chica1 | |
26/5/2023 10:33 | I think I would prefer to have as an independent NED someone who didn't have quite so much history with Open Orphan (and therefore presumably with CF, the major shareholder of POLB). | 1gw | |
26/5/2023 10:15 | When are we expecting news from the collaboration with Onetree? Brendan Buckley has been a director at (OO)Hvivo for the last 3 years so no surprise there. He's also a director at Imutex. Obviously he's Cathal Friel's goto guy in the medical space. | chica1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions